Recent Quotes (30 days)

You have no recent quotes
chg | %

AstraZeneca plc news

   Watch this stock
Showing stories 11 - 20 of about 157   

Articles published

AZN 5,068.51 -22.49 (-0.44%)
price chart
AstraZeneca plc (ADR) (AZN): Double Success in Oncology Portfolio Could Prove ...
AstraZeneca plc (ADR) (NYSE:AZN) has announced mutual collaboration with Rpositive, a Cambridge software firm, for the research and development of oncology molecules to treat different categories.
Is AstraZeneca A Buy After Opdivo Failure?  Seeking Alpha
Generics hound AstraZeneca despite Brilinta star turn
AstraZeneca's (LON:AZN) profits and sales both fell as patent expiries and heavy restructuring took their toll on the UK pharma's first half.
AstraZeneca's Earnings Meet Estimates as New Drug Sales Rose  Bloomberg
AstraZeneca swings to loss, missing forecasts  MarketWatch
AstraZeneca combination fails final lung cancer trial, Array hit
Sean Bohen, global medicines development and chief medical officer at AstraZeneca, said the result was disappointing especially after promising results from the combination in the Phase II trial.
Will AstraZeneca plc Capture the Lung Cancer Market?  Bidness ETC
AstraZeneca Cancer Drug Selumetinib Fails in Lung Trial  Bloomberg
AstraZeneca plc (ADR) (AZN) Got Breakthrough In The UK Market
AstraZeneca plc (ADR) (NYSE:AZN) has huge expectations with its blood thinner drug Brilinta (ticagrelor) to generate revenue in the years to come.
AstraZeneca plc 16% Potential Upside Indicated by Deutsche Bank
AstraZeneca plc with EPIC/TICKER LON:AZN has had its stock rating noted as 'Retains' with the recommendation being set at 'BUY' this morning by analysts at Deutsche Bank.
AstraZeneca plc (AZN) Given a GBX 4000 Price Target at Goldman Sachs Group Inc.  The Cerbat Gem
AstraZeneca plc (AZN) Receives "Outperform" Rating from BNP Paribas  Community Financial News
Will AstraZeneca plc (AZN) Survive Crestor Loss?
Despite extreme efforts from AstraZeneca plc (ADR) (NYSE:AZN) for the patent extension of its famous drug, Crestor, a federal judge has declined its request to ban the launching of Crestor generics and biosimilar versions.
AstraZeneca plc (ADR) Stock Open to Further Upside; Here's Why  Bidness ETC
AstraZeneca plc 5.3% Potential Decrease Indicated by JP Morgan Cazenove
AstraZeneca plc using EPIC/TICKER code LON:AZN has had its stock rating noted as 'Reiterates' with the recommendation being set at 'NEUTRAL' today by analysts at JP Morgan Cazenove.
Stock's Earning Overview: Astrazeneca PLC (NYSE:AZN)  News Oracle
Shore Capital Reiterates Hold Rating for AstraZeneca plc (AZN)  The Cerbat Gem
Shire PLC Lags GlaxoSmithKline plc, AstraZeneca plc, Pfizer Inc. And Johnson ...
This is less than the gains made by global sector peers such as GlaxoSmithKline plc (LON: GSK), AstraZeneca plc (LON: AZN), Pfizer Inc. (NYSE: PFE) and Johnson & Johnson (NYSE: JNJ).
Key Analyst's EPS Estimates: Astrazeneca PLC (NYSE:AZN)
Astrazeneca PLC (NYSE:AZN) finished the trade at $33.56, lower -0.03%. Its last's traded volume was 3.27 million shares in comparison to its average trading volume of 6.07 million shares.
AstraZeneca Transcends Brexit Woes on Pound Slump, Rival's Flop
AstraZeneca Plc, once deemed a laggard in the hot field of immuno-oncology, has rallied 37 percent since its June low with a stable of experimental cancer drugs suddenly gaining allure in the wake of a rival's failure and speculation of a takeover.